A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk
一项针对绝经后患有骨质疏松症和高骨折风险的中国女性的III期随机、双盲、安慰剂对照试验，评估了地诺单抗生物类似药QL1206的疗效。
期刊:Acta Pharmacologica Sinica
影响因子:8.4
doi:10.1038/s41401-022-00954-y
Zhang, Hao; Gu, Jie-Mei; Chao, Ai-Jun; Cheng, Qun; Teng, Dong-Hui; Yu, Jin-Ming; Wang, Bing-Wu; Huo, Ya-Nan; Mao, Li; Zhang, Qiu; Yang, Hong; Yan, Shi-Gui; Zhang, Ke-Qin; Zhao, Xue-Ling; Lin, Hua; Pei, Yu; Yuan, Zhong; Dai, Ru-Chun; He, Liang; Chen, Li; Su, Yong-Feng; Deng, Zhong-Liang; You, Li; Ban, Bo; Zhu, Mei; Cao, You-Liang; Zhu, Yi-Kun; Li, Zhi-Jun; Zhang, Zhi; Yi, Cheng-Qing; Lu, Yi-Bing; Wang, Guang; Han, Cui-Cui; Wang, Zhen-Jiang; Li, Xian-Xing; Zhang, Zhen-Lin
